Seqens Seqens

X
[{"orgOrder":0,"company":"Cadrenal Therapeutics","sponsor":"The Sage Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"}]

Find Clinical Drug Pipeline Developments & Deals for MolPort-002-130-141

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the partnership, Sage Group will assist Cadrenal in exploring strategic partnerships, co-development and licensing agreements for ATI-5923 (tecarfarin), a late-stage, novel, oral and reversible anticoagulant designed to prevent heart attacks, strokes and deaths.

            Lead Product(s): Tecarfarin,Warfarin Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ATI-5923

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: The Sage Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership December 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY